Durham, North Carolina-based Dova Pharmaceuticals, which is focused on buying, developing and commercializing drug candidates for rare diseases, raised about $75.1 million after pricing its over 4.41 million shares at $17 per share. The stock began trading June 29, 2017 on the NASDAQ under the ticker symbol “DOVA.” J.P. Morgan Securities LLC, Jefferies LLC and Leerink Partners were the underwriters. Dova’s backers included PBM Capital Investments and Perceptive Life Sciences.
DURHAM, N.C., June 28, 2017 (GLOBE NEWSWIRE) — Dova Pharmaceuticals, Inc. (NASDAQ:DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare diseases where there is a high unmet need, today announced the pricing of its initial public offering of 4,415,000 shares of its common stock at a public offering price of $17.00 per share, for total gross proceeds of approximately $75.1 million. In addition, Dova has granted the underwriters a 30-day option to purchase up to an additional 662,250 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the common stock is being offered by Dova. The shares are scheduled to begin trading on the NASDAQ Global Market on June 29, 2017 under the ticker symbol “DOVA.” The offering is expected to close on July 5, 2017, subject to customary closing conditions.
J.P. Morgan Securities LLC, Jefferies LLC and Leerink Partners LLC are serving as joint book-running managers for the offering.
A registration statement relating to the securities being sold in this offering was declared effective by the Securities and Exchange Commission on June 28, 2017. This offering is being made only by means of a prospectus. A copy of the final prospectus can be obtained, when available, from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by phone at 1-877-821-7388 or by email at Prospectus_Department@Jefferies.com; or Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6132 or by email at email@example.com.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Dova Pharmaceuticals, Inc.
Dova is a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare diseases where there is a high unmet need, with an initial focus on addressing thrombocytopenia. The company’s lead drug candidate, avatrombopag, recently completed two pivotal Phase 3 clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease undergoing planned medical procedures.